What happened
Corologic, a medical AI company founded in May 2026, announced it has raised seed funding from Kakao Ventures and SNU Holdings. The company is developing AngioFilm, an AI-based video frame interpolation tool designed to reduce radiation exposure during coronary angiography by generating high-frame-rate video from low-frame-rate inputs. The startup plans to use the capital to pursue multicenter clinical validation and regulatory approvals, including FDA 510(k) clearance and ISO 13485 certification.
Corologic, a cardiovascular imaging artificial intelligence startup, announced on September 15 that it has raised seed funding from Kakao Ventures and SNU Holdings. The company was founded in May 2026 by a team led by Professor Kang Si-hyuk of the division of cardiology at Seoul National University Bundang Hospital.
The startup is developing a product called AngioFilm, which uses AI-based video frame interpolation (VFI) to restore angiography footage shot at a low frame rate into what appears to be high-frame-rate video in real time. The AI analyzes the position and movement of blood vessels and medical devices in preceding and following frames to estimate intermediate views, thereby generating new frames. This process aims to reduce the number of X-ray images captured while allowing medical staff to follow vessel movement without interruption.
AngioFilm is designed with a low adoption burden, as it can be linked to existing angiography equipment without replacing existing machines. It utilizes an 'edge' approach that processes images in real time within the hospital environment. In May 2026, Corologic presented related research findings and demonstrated the product at EuroPCR 2026 in Paris. In August 2026, the company participated in the Korea International Hospital & Healthcare Industry Fair (KHF 2026) and completed a medical device filing with the Ministry of Food and Drug Safety.
The company plans to use the seed funding to pursue multicenter clinical validation and broader regulatory approvals, including from the Korean drug safety ministry, U.S. Food and Drug Administration 510(k) clearance, and ISO 13485 global quality certification. Jung Joo-yeon, a senior investment manager at Kakao Ventures, noted that the solution is standalone and not tied to any particular equipment manufacturer, seeing potential for global market expansion.
Source details: en.sedaily.com ↗
Why it matters
This funding supports the development of a practical AI application in medical imaging that addresses a specific safety concern: radiation exposure for both patients and medical staff during cardiovascular procedures. By using AI to interpolate video frames, the technology aims to reduce the number of X-ray images required without compromising the visual continuity needed for medical staff to track vessel movement. The investment signals growing interest in AI solutions that enhance procedural safety and efficiency in clinical settings, particularly those that can integrate with existing hospital infrastructure without requiring hardware replacement.
Radiation exposure is a significant safety concern in cardiovascular interventions such as coronary angiography, affecting both patients and the medical staff who perform the procedures. Corologic's AI solution addresses this by reducing the frequency of X-ray captures while maintaining the visual information necessary for procedural guidance.
The technology's ability to integrate with existing hospital infrastructure without requiring new hardware makes it a potentially scalable solution for healthcare systems looking to improve safety without major capital expenditure on equipment replacement.
The involvement of Kakao Ventures and SNU Holdings indicates investor confidence in the commercial and clinical potential of AI-driven medical imaging tools that offer tangible safety benefits in high-stakes clinical environments.
What to watch next
Investors and healthcare providers should monitor Corologic's progress in completing multicenter clinical trials and obtaining regulatory clearances from the Korean Ministry of Food and Drug Safety and the U.S. FDA. The success of these validations will determine the commercial viability of AngioFilm and its potential for global adoption in cardiovascular intervention suites.
The outcome of Corologic's multicenter clinical validation studies will be critical in demonstrating the efficacy and safety of AngioFilm in real-world clinical settings.
Progress toward obtaining regulatory clearances from the U.S. FDA and international bodies will determine the timeline for global commercialization and adoption of the technology.
The company's ability to secure partnerships with hospital networks and medical device manufacturers will be key to scaling the deployment of AngioFilm in cardiovascular procedure suites.